333 related articles for article (PubMed ID: 25355245)
1. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
[TBL] [Abstract][Full Text] [Related]
2. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Dueck G; Chua N; Prasad A; Finch D; Stewart D; White D; van der Jagt R; Johnston J; Belch A; Reiman T
Cancer; 2010 Oct; 116(19):4541-8. PubMed ID: 20572046
[TBL] [Abstract][Full Text] [Related]
3. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
6. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
[TBL] [Abstract][Full Text] [Related]
9. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in relapsed refractory non-Hodgkin's lymphoma: An Indian perspective.
Lakshmaiah KC; Rachan Shetty KS; Sathyanarayanan V; Lokanatha D; Abraham LJ; Babu KG
J Cancer Res Ther; 2015; 11(4):857-61. PubMed ID: 26881531
[TBL] [Abstract][Full Text] [Related]
11. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
[TBL] [Abstract][Full Text] [Related]
12. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
[TBL] [Abstract][Full Text] [Related]
13. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Vose JM; Habermann TM; Czuczman MS; Zinzani PL; Reeder CB; Tuscano JM; Lossos IS; Li J; Pietronigro D; Witzig TE
Br J Haematol; 2013 Sep; 162(5):639-47. PubMed ID: 23834234
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Ishida T; Fujiwara H; Nosaka K; Taira N; Abe Y; Imaizumi Y; Moriuchi Y; Jo T; Ishizawa K; Tobinai K; Tsukasaki K; Ito S; Yoshimitsu M; Otsuka M; Ogura M; Midorikawa S; Ruiz W; Ohtsu T
J Clin Oncol; 2016 Dec; 34(34):4086-4093. PubMed ID: 27621400
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Choueiri TK; Dreicer R; Rini BI; Elson P; Garcia JA; Thakkar SG; Baz RC; Mekhail TM; Jinks HA; Bukowski RM
Cancer; 2006 Dec; 107(11):2609-16. PubMed ID: 17075879
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
[TBL] [Abstract][Full Text] [Related]
17. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
18. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Czuczman MS; Vose JM; Witzig TE; Zinzani PL; Buckstein R; Polikoff J; Li J; Pietronigro D; Ervin-Haynes A; Reeder CB
Br J Haematol; 2011 Aug; 154(4):477-81. PubMed ID: 21707581
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
Zhang MM; Chan JK; Husain A; Guo HY; Teng NN
Gynecol Oncol; 2007 Apr; 105(1):194-8. PubMed ID: 17257661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
